Pediatr Gastroenterol Hepatol Nutr.  2024 Mar;27(2):104-112. 10.5223/pghn.2024.27.2.104.

Incidence of Low Seroimmunity to Hepatitis B Virus in Children with Inflammatory Bowel Disease: A Single Center Experience

• Mansour HH
• Eskander AE
• Osman SM
• Rady NH

• KMID: 2554073
• DOI: http://doi.org/10.5223/pghn.2024.27.2.104

Abstract

Purpose
Immunosuppressive therapy is frequently administered to patients with inflammatory bowel disease (IBD), which may make them more susceptible to infections like hepatitis B.
Methods
A cross-sectional study was conducted on patients aged 5–18 years diagnosed with IBD who visited a gastroenterology clinic along with controls who were the same age as the patients with IBD and were healthy overall. A logistic regression analysis using the independent variables of age, sex, race, disease phenotype, surgery, and medications and the dependent variable of adequate hepatitis B surface antibody (HBsAb) titers (>10 mIU/mL) was performed on quantitative serum HBsAb titers.
Results
The study enrolled 62 patients, including 37 males and 25 females. Crohn’s disease, ulcerative colitis, and indeterminate colitis were diagnosed in 16, 22, and 24 patients, respectively. Thirty-nine patients were taking corticosteroids at the time of the study, 42 were taking immunomodulators, and four were taking biologics. Compared to 44.7% of the control group, 9.3% of the patients had protective titers. Only 12 out of 62 patients had HBsAb titers greater than 10 million IU/mL. None of the patients who received biologics or corticosteroids and 3.2% of those who received immunomodulators were found to be seroimmuned.
Conclusion
The younger patients had the highest titers. Patient-specific factors that may impact these low titers include the length of the patient’s illness and the use of immunosuppressants.

Keyword

Inflammatory bowel disease; Hepatitis B surface antibody